ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.

Susana Banerjee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.